<DOC>
	<DOCNO>NCT00414102</DOCNO>
	<brief_summary>The purpose study determine subjective treatment effect ramelteon , daily ( QD ) , sleep use post sleep questionnaire-interactive voice response system adult chronic insomnia .</brief_summary>
	<brief_title>Subjective Efficacy Ramelteon Sleep Adults With Chronic Insomnia .</brief_title>
	<detailed_description>Approximately 60 70 million adult United States alone affect insomnia . Daytime symptoms insomnia include tiredness , lack energy , difficulty concentrating , irritability . Recent epidemiologic research focus quality life identify significant insomnia-related condition relate work productivity , health care utilization , risk depression . Insomnia associate diminished work output , absenteeism , great rate accident . Ramelteon market treatment insomnia characterize difficulty sleep onset brand name Rozeremâ„¢ . This study comprise two group subject , 1 ) outpatient group 2 ) inpatient group . The inpatient group use reference arm previously conduct study sleep laboratory setting . Study participation anticipate 50 day ( approximately 1.75 month ) .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Body mass index 18 34 , inclusive . Based sleep history , chronic insomnia least 3 month . Based sleep history , report history subjective sleep latency great equal 60 min subjective total sleep time le equal 6.5 hour . The difference average subjective sleep latency day 13 day 57 less equal 20 minute single blind runin period . On least 3 first 5 night singleblind runin placebo treatment , subject must subjective sleep latency great equal 45 minute subjective total sleep time le equal 6.5 hour . Based sleep history , habitual bedtime 10:00 PM 1:00 AM . Willing fixed bedtime agree go bed within 30 minute habitual bedtime entire study . Consistent access touchtone phone willing complete paper telephone questionnaire within 60 minute awaken morning throughout entire duration study . Willing remain bed least 6.5 hour night entire study . Based sleep history , use pharmacological assistance sleep 0 4 time per week last 3 month . Exclusion Criteria Known hypersensitivity ramelteon related compound , include melatonin , melatonin related compound . Participated investigational study and/or take investigational drug within 30 day five halflives prior first dose singleblind study medication , whichever longer . Has sleep schedule change require employment ( eg , shift worker ) within three month prior administration singleblind study medication . Has fly across great 3 time zone within 7 day prior screen , travel across 2 time zone course study . Has participate weight loss program substantially alter exercise routine within 30 day prior first night singleblind study medication . Has ever history seizure ; sleep apnea , restless leg syndrome , periodic leg movement syndrome , chronic obstructive pulmonary disease , fibromyalgia , positive test result aforementioned ailment screen polysomnography . History psychiatric disorder within past 6 month . History drug addiction drug abuse within past 12 month . History alcohol abuse within past 12 month , define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised , regularly consume 14 alcoholic drink per week , inpatient subject consume alcoholic drink within 24 hour polysomnography visit . Current significant hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematological , neurological , metabolic disease , unless currently control stable protocolallowed medication , within 30 day prior first night singleblind study medication . Uses tobacco product product nightly awakening may interfere sleep wake cycle . Positive urine drug screen initial screen Visit 2 . For inpatient subject : positive breathalyzer test PSG assessment visit . Exhibit placebo response single blind placebo run period . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Any additional condition ( ) Investigator 's opinion would : affect sleep/wake function prohibit subject complete study indicate continuation study would best interest subject . Positive hepatitis panel include hepatitis A virus Immunoglobulin M , hepatitisB surface antigen , hepatitis C virus antibody . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include follow : Anxiolytics Antipsychotics overthecounter Prescription Sedatives Hypnotics Narcotic analgesic Antidepressants Betablockers Anticonvulsants St. John 's wort Sedating H1 antihistamines Kavakava Systemic steroid Ginkgobiloba Respiratory stimulant overthecounter prescription diet aid Sedating Decongestants Muscle relaxant Melatonin drug supplement know affect sleep/wake function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>Sleep Initiation Maintenance Disorder</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>